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Abstract Constitutive tumor necrosis factor-K expression
(TNF-K) has been detected in first trimester trophoblast cells
and differentiated syncytiotrophoblasts. However, molecules
which induce TNF-K release from these cells and their
mechanism of action have not been defined. We show for the
first time that interleukin-1 (IL-1), a regulator of trophoblast
development, induces TNF-K expression in proliferating cyto-
trophoblastic cells and purified term trophoblasts. Both IL-1K
and L stimulate TNF-K release from BeWo cells and TNF-K
mRNA was transiently expressed. In growth-arrested/differen-
tiated BeWo cells TNF-K mRNA was detectable without
inducer, however, in the presence of IL-1L TNF-K secretion
was weakly stimulated compared to proliferating cells. Cyclo-
heximide strongly increased IL-1L-induced TNF-K mRNA
concentration indicating that de novo protein synthesis is not
required for TNF-K gene expression. However, treatment with
cycloheximide did not prevent IL-1L-stimulated release of TNF-
K, indicating that the cytokine can regulate TNF-K secretion at a
posttranslational level, independently of TNF-K mRNA induc-
tion. Besides demonstration of this novel mechanism of IL-1-
stimulated TNF-K expression, our data indicate an important
role of IL-1 in TNF-K production of cytotrophoblastic cells.
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1. Introduction
Tumor necrosis factor-K (TNF-K), originally identi¢ed in
macrophages, is a proin£ammatory cytokine which exhibits
pleiotropic e¡ects on cells. TNF-K not only inhibits growth
of certain tumors, but alters proliferation, di¡erentiation and
metabolism of a variety of cells (reviewed in [1]). The role of
TNF-K in various physiological processes was demonstrated,
ranging from in£ammation and protection against infections
to embryogenesis and hematopoiesis [2,3]. Besides its physio-
logical roles TNF-K was shown to be involved in a variety of
diseases and was described as the major mediator of septic
shock [4]. The biological properties of the protein are sig-
nalled through two distinct receptors (p55 and p75) which
mediate their responses via di¡erent signal transducers [5].
Within the reproductive tract the in£uence of TNF-K on
pregnancy-speci¢c hormone expression has been demon-
strated. TNF-K was shown to a¡ect progesterone, estradiol
and human chorionic gonadotropin (hCG) production in pla-
cental fragments and JEG-3 choriocarcinoma cells [6]. More-
over, mouse placental lactogen II expression in trophoblast
cells was selectively inhibited by TNF-K through TNF-K
type I receptor [7].
Endogenous uterine TNF-K expression was originally de-
tected in human decidua and the amniotic £uid [8,9] and in
the murine placenta [10]. In pregnant rats TNF-K mRNA was
shown to be localized in uterine epithelial, decidual and
trophoblast giant cells as well as in placental macrophages.
In the latter, however, immunoreactive TNF-K could not be
identi¢ed which suggested that macrophages do not contrib-
ute to placental TNF-K production under normal physiolog-
ical conditions [11]. In the human placenta, TNF-K mRNA
and protein [12] and a low-a¤nity TNF receptor [13] were
shown to be expressed in placental syncytiotrophoblasts. By
in situ hybridization TNF-K transcripts were also detected in
cytotrophoblast cells isolated from early gestation tissue and
TNF-K protein was immunocytochemically identi¢ed in cho-
riocarcinoma cells used as a model for proliferating tropho-
blasts [14]. However, secretion of TNF-K from growing cho-
riocarcinoma cells [14] was either low (Jar cells) or undetect-
able (JEG-3 cells) suggesting that in vivo additional factors
might be required for TNF-K release from cytotrophoblasts.
Therefore, we were interested to evaluate whether interleu-
kin-1 (IL-1), which is known to play an important role in
placentation, might stimulate TNF-K expression in tropho-
blast cells. In this paper we demonstrate that IL-1 induces
TNF-K secretion from proliferating choriocarcinoma cells as
well as from puri¢ed villous trophoblasts isolated from term
placenta. Moreover, we show that IL-1L enhances TNF-K
mRNA expression in BeWo cells and stimulates release of
preformed TNF-K protein by an independent mechanism.
2. Materials and methods
2.1. Isolation of term trophoblast cells
Term trophoblast cells were isolated from selected placental tissue
between 38 and 41 weeks of gestation after spontaneous delivery or
cesarean section. Brie£y, tissue was subjected to two trypsin (0.125%)/
DNase I (0.16 mg/ml) digestions. After sedimentation of tissue par-
ticles, cell suspension from the supernatant was fractionated on a 5^
70% discontinuous Percoll gradient (Pharmacia Biotech, Uppsala,
Sweden) as previously described [15]. To remove remaining leukocytes
trophoblast cells were further incubated with a CD45 antibody
coupled to magnetic beads (Dynal, Oslo, Norway). Purity of tropho-
blasts was determined on cytospins by counting positive cells after
immunocytochemical detection with an anticytokeratin antibody as
described [16]. Cells with a purity of 85^90% were cultivated on 24-
well plates in DMEM supplemented with 10% fetal bovine serum
(FBS) and antibiotics (100 IU/ml penicillin, 100 Wg/ml streptomycin)
in a humidi¢ed incubator with 5% CO
2
and 95% air. Cells were
seeded at a density of 1U10
5
cells/cm
2
. After 24 h in culture, medium
was changed and human recombinant interleukin-1 (R and D Sys-
tems, Abingdon, UK) was added to a ¢nal concentration of 2.5 ng/ml.
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2.2. Cultivation of choriocarcinoma cells
Choriocarcinoma cell lines were obtained from American Type Cul-
ture Collection (Rockville, MD). BeWo choriocarcinoma cells (ATCC
CCL-98) were grown in DMEM supplemented with 10% FBS and
antibiotics (100 IU/ml penicillin, 100 Wg/ml streptomycin). JAR cho-
riocarcinoma cells (ATCC HTB-144) were cultured in RPMI 1640
medium with the same supplements. Cells were maintained under
standard tissue culture conditions in a humidi¢ed incubator with
5% CO
2
and 95% air. For treatment with cytokines, cells were seeded
at a density of 2U10
5
cells/cm
2
. After one additional day in culture
fresh medium containing human recombinant IL-1K or IL-1L was
added. For induction of growth arrest/di¡erentiation cells were
treated with 1 WM methotrexate (MTX, Sigma Chemical Co., St.
Louis, MO, USA) added to the growth medium. Induction of TNF-
K release was performed by addition of 2.5 ng/ml IL-1L, 48 h after
addition of MTX. To inhibit protein synthesis, BeWo cells were in-
cubated for 2 h in the presence of 10 Wg/ml cycloheximide (Sigma
Chemical Co.) prior to the addition of IL-1L.
2.3. Measurement of TNF-K from cell culture supernatants
Supernatants were aspirated from cell cultures and frozen on dry ice
after various times of incubation with IL-1K or L. TNF-K concentra-
tion was determined twice in each sample by a one-step `sandwich'
enzyme immunoassay (Immunotech, Marseille, France) according to
the instructions of the manufacturer. The sensitivity of the assay in
culture supernatant was limited to 10 pg/ml. As speci¢ed by the sup-
plier, there is no detectable cross-reactivity with either TNF-L or
di¡erent forms of TNF receptors.
2.4. Isolation and hybridization of RNA
Total RNA was isolated from cells by direct lysis within the culture
£ask using TRI Reagent (Molecular Research Center Inc., Cincinnati,
OH, USA) according to the manufacturer's instructions. For North-
ern blot analyses, equal amounts of RNA (20 Wg) were glyoxylated
and separated by electrophoresis on agarose gels as described [17].
The fractionated RNA was transferred from gels to nylon membranes
(Gene Screen, DuPont NEN), crosslinked to the membrane by UV
irradiation, hybridized to the
32
P-labelled TNF-K cDNA (ATCC
53007), washed and exposed to X-ray ¢lms. Radiolabelling of
cDNA was performed using the Megaprime DNA labelling system
according to the instructions of the manufacturer (Amersham, Buck-
inghamshire, UK). All hybridizations were performed in 50% forma-
mide, 5USSC, 1UDenhardt's solution, 50 mM sodium phosphate
(pH 6.5) and 200 Wg/ml single-stranded salmon sperm DNA for 24
h at 42³C. The last post-washes were in 0.2USSC/0.1% SDS at 65³C.
Filters were stripped and rehybridized with a
32
P-labelled glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) cDNA fragment. Auto-
radiographs were densitometrically scanned and quanti¢cation of
TNF-K mRNA signals was done with Pdi Analysis Software for Bio-
logical Data. Hybridization signals of TNF-K were normalized ac-
cording to the GAPDH signals.
3. Results
Upon addition of human recombinant IL-1L into the cul-
ture medium of choriocarcinoma cells and isolated term
trophoblasts we observed a time-dependent increase of
TNF-K within the supernatant. In proliferating cytotropho-
blastic cells TNF-K release was rapidly induced. 6 h after
the addition of 2.5 ng IL-1L we detected 360 pg/ml and 393
pg/ml TNF-K in the culture medium of BeWo and Jar cells,
respectively (Fig. 1). Compared to the choriocarcinoma cell
lines we observed a slightly di¡erent kinetics of TNF-K release
from puri¢ed term trophoblast cells and we only detected 248
pg/ml TNF-K 18 h after IL-1L addition (Fig. 1). We have also
measured TNF-K secretion from BeWo, Jar and term tropho-
blasts in the absence of IL-1L at di¡erent times in culture.
However, we could not detect quanti¢able amounts of the
protein suggesting that in non-stimulated cells TNF-K levels
were below the detection limit of the enzymatic TNF-K assay
(910 pg/ml). In BeWo and Jar choriocarcinoma cells TNF-K
secretion was further increased up to 1 ng/ml when cells were
incubated for 24 h in the presence of IL-1L (Fig. 1).
TNF-K release from BeWo cells was induced by IL-1K as
well as IL-1L in a dose-dependent manner. Addition of 10 pg/
ml of human recombinant IL-1K or IL-1L to the culture me-
dium induced quanti¢able amounts of TNF-K after 8 h of
stimulation (Fig. 2A) and 10 ng/ml of each cytokine strongly
enhanced TNF-K release. However, IL-1L was found to be
more e¡ective than IL-1K, at least in the range of 0.1^1 ng/
ml. Furthermore, we investigated the time-dependent induc-
tion of TNF-K secretion in BeWo cells treated with the same
amounts of either IL-1K or IL-1L (Fig. 2B). Consistently,
TNF-K values quantitated from IL-1L-stimulated cells were
higher than those measured in the supernatants isolated
from IL-1K-incubated cells indicating that IL-1L was indeed
the better inducer.
To investigate the molecular mechanism of IL-1-induced
TNF-K expression in more detail, we performed Northern
transfer of RNA isolated from IL-1L-stimulated and non-
stimulated BeWo cells and hybridization with the
32
P-labelled
TNF-K cDNA (Fig. 3). While TNF-K transcripts were unde-
tectable in total RNA from non-induced cells, we observed a
1.9 kb transcript in IL-1L-stimulated cells after a short expo-
sure to ¢lms. Hybridization was speci¢c to the TNF-K mRNA
because the
32
P-labelled cDNA detected the TNF-K transcript
from lipopolysaccharide-stimulated U937 cells (data not
shown). After rapid induction TNF-K mRNA abundance de-
creased 3.5-fold within 4 h (Fig. 3) and was almost undetect-
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Fig. 1. Stimulation of TNF-K secretion upon addition of IL-1L.
BeWo and Jar choriocarcinoma cells were seeded in T25 £asks at a
density of 2U10
5
cells/cm
2
and cultured for an additional 24 h be-
fore induction with 2.5 ng/ml human recombinant IL-1L. Term
trophoblasts were puri¢ed as described in Section 2, seeded at a
density of 1U10
5
/cm
2
and treated with 2.5 ng/ml IL-1L. Cell culture
supernatants were isolated after 0, 6, 12, 18 and 24 h of stimulation
and TNF-K concentration was determined by ELISA. Open and
¢lled circles indicate TNF-K values obtained from Jar and BeWo
cells, respectively. Open squares represent values measured in super-
natants from puri¢ed term trophoblasts. Values are the mean from
three independent experiments, error bars represent S.D.
M. Kno
ë
£er et al./FEBS Letters 405 (1997) 213^218214
able after 18 h of incubation (not shown). Usually, peak levels
of TNF-K mRNA were observed between 1 and 2 h after
induction depending on the experiment. Conversely, TNF-K
concentrations in the supernatant of the same cells steadily
increased up to 318 pg/ml after 4 h of incubation.
To determine whether de novo protein synthesis might be
required for TNF-K mRNA expression we performed IL-1L
induction after treatment with cycloheximide, a potent inhib-
itor of protein translation. BeWo cells were preincubated for
2 h in the presence of cycloheximide and, subsequently, either
stimulated or not stimulated with the cytokine (Fig. 4). Incu-
bation of cells with cycloheximide alone resulted in an in-
crease of TNF-K mRNA; however, active TNF-K was not
released, since the protein could not be detected in the super-
natant. Addition of IL-1L to translationally inhibited cells
strongly induced TNF-K mRNA expression indicating that
the induction of TNF-K transcripts was independent of new
protein synthesis. Interestingly, secretion of TNF-K was not
abolished under those conditions. After 6 h of incubation with
IL-1L we detected 248 pg/ml and 372 pg/ml of TNF-K in
cycloheximide-treated and untreated cells, respectively. Con-
tinuous TNF-K release in the presence of cycloheximide and
IL-1L was also observed in a second, independent experiment
(not shown).
Finally, we analyzed the in£uence of growth arrest and/or
di¡erentiation on IL-1-inducible TNF-K release. BeWo cells
were incubated in the presence of MTX and then incubated in
the presence of IL-1L. Cells which had received the drug for
48 h did not divide in culture, since we could not detect an
increase in cell number relative to the starting culture. How-
ever, cells were viable, as was estimated by trypan blue exclu-
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Fig. 2. A: IL-1K and IL-1L induce TNF-K release in a dose-depend-
ent manner. BeWo cells were seeded at a density of 2U10
5
cells/cm
2
and incubated with di¡erent amounts of recombinant human IL-1K
(hatched bars) or IL-1L (open bars). After 8 h supernatants were
isolated and TNF-K concentration was determined by enzyme im-
munoassay. Bars represent the range in two experiments. B: Time-
dependent TNF-K release upon addition of IL-1K or IL-1L. BeWo
cells, seeded at a density of 2U10
5
cells/cm
2
, were incubated with
3 ng of human recombinant IL-1K or IL-1L. Cell culture super-
natants were aspirated after 1, 2, 4 and 6 h and TNF-K concentra-
tion was determined as described above. Hatched and open bars in-
dicate TNF-K values after stimulation with IL-1K or IL-1L,
respectively. Bars represent the range in two experiments.
Fig. 3. TNF-K mRNA expression in IL-1L-induced BeWo cells.
BeWo cells were incubated in the presence of 2.5 ng/ml human re-
combinant IL-1L. Supernatants were aspirated from cells 0, 1, 2,
and 4 h after IL-1L addition and total RNA was prepared as de-
scribed in Section 2. TNF-K mRNA expression was visualized by
hybridization with the
32
P-labelled TNF-K cDNA. Quanti¢cation of
signals was performed by densitometric scanning of the autoradio-
graphs. TNF-K values were normalized to GAPDH hybridization in
each sample. TNF-K release was quantitated from supernatants by
ELISA. TNF-K and GAPDH mRNA (arrows) and TNF-K concen-
tration in the medium (open bars) are indicated.
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sion, and hCG secretion, measured by RIA, was 3.5-fold in-
duced suggesting functional di¡erentiation (data not shown).
Contrary to proliferating cells, MTX-treated cells displayed
TNF-K mRNA expression and protein secretion without
any inducer (Fig. 5). When IL-1L was added TNF-K
mRNA expression and TNF-K release were enhanced in
both growing as well as non-growing cells. In proliferating
cells the TNF-K concentration rose to 182 pg/ml within 2 h
while in di¡erentiated cells 319 pg/ml was detected. However,
the relative induction in MTX-treated cells was only 2.2-fold
between 0 and 2 h suggesting that inducible secretion of the
cytokine was downregulated in resting cells.
4. Discussion
TNF-K was found to be expressed in cytotrophoblasts, cho-
riocarcinoma cells and syncytiotrophoblasts [12,14], and its
role in placental hormone secretion has been demonstrated
[6,18]. However, to our knowledge, factors which actually
stimulate the release of TNF-K from trophoblast cells were
not described. Therefore, we have investigated TNF-K expres-
sion in the presence of IL-1L, another cytokine which is in-
volved in the trophoblast-di¡erentiation process. IL-1L has
been detected in maternal decidua during pregnancy [19,20]
and was shown to stimulate aromatase activity [21], secretion
of hCG from cytotrophoblasts [22], and metalloproteinase
activity, thereby modulating trophoblast invasion [23]. Here,
we demonstrate that IL-1L e¤ciently induces TNF-K release
from proliferating BeWo and JAR choriocarcinoma cells and
puri¢ed term trophoblasts in culture. Both IL-1K and L stim-
ulate TNF-K secretion with doses as low as 10 pg/ml, suggest-
ing that IL-1 could also be an important regulator of TNF-K
expression in vivo. Secreted TNF-K protein might control
proliferation of cytotrophoblasts by positive feedback on the
TNF-p60 receptor, which is required for ongoing DNA syn-
thesis in cytotrophoblastic cells [14]. On the other hand, IL-1L
was shown to decrease proliferation of cultured BeWo cells in
a dose-dependent manner [24] which might be explained by
the cytostatic e¡ects of TNF-K. Indeed, TNF-K was shown to
induce apoptosis in primary cytotrophoblasts and syncytiotro-
phoblasts and a role in the regulation of trophoblast turnover
has been suggested [25,26]. In vivo, however, trophoblast cells
are exposed to a complex mixture of cytokines and their an-
tagonists. Therefore, the cytotoxic e¡ects of TNF-K might be
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Fig. 4. The in£uence of cycloheximide on Il-1L-induced TNF-K mRNA expression and protein release. BeWo cells were treated for 2 h with 10
Wg/ml cycloheximide (C) and then incubated with or without 2.5 ng/ml IL-1L. As a control, cells which did not receive cycloheximide treatment
were stimulated with the same amount of IL-1L. Cell supernatants and RNA were isolated after 2, 4, and 6 h of incubation. TNF-K protein in
the medium (open bars) and TNF-K and GAPDH mRNA were analyzed as described above.
Fig. 5. Inducible TNF-K mRNA expression and secretion in prolif-
erating and growth-arrested cells. BeWo cells were seeded at a den-
sity of 4U10
5
cells/cm
2
. Before reaching con£uency medium with or
without 1 WM methotrexate was added. Cells were cultivated for an
additional 48 h and 2.5 ng/ml recombinant IL-1L was added. Cell
culture supernatants as well as RNA were isolated after 0, 0.5, 1 and
2 h and analyzed as described above. To compare the release of ac-
tive TNF-K from proliferating and di¡erentiated cells, TNF-K pro-
tein concentrations (open bars) were normalized to the individual
cell number of MTX-treated and non-treated cultures.
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counteracted by soluble TNF receptors which are e¤ciently
secreted from ¢rst trimester trophoblastic villi [27].
Expression of the human TNF-K gene was shown to be
regulated at multiple levels, including gene transcription, turn-
over of TNF-K mRNA and protein processing (reviewed in
[28]). The TNF-K promoter contains several recognition se-
quences for NF-UB [29] but depending on cell type and stim-
ulus, distinct combinations of binding sites as well as di¡erent
factors are required for transcriptional activation [30]. IL-1-
induced increase of IL-6 mRNA is performed by NF-UB ac-
tivation, which has also been implicated in IL-1-mediated
TNF-K gene transcription [31].
TNF-K mRNA production has been detected in poly A

RNA from choriocarcimona cells [14] ; however, in total RNA
isolated from non-stimulated BeWo cells we did not observe
TNF-K transcripts after short exposure suggesting that con-
stitutive mRNA expression is low. Upon addition of IL-1L
TNF-K mRNA was easily detectable under our experimental
conditions and we observed a transient TNF-K mRNA ex-
pression which is typical of NF-UB-activated genes [32].
Although we have not measured gene transcription directly,
we demonstrate that IL-1-induced increase of TNF-K mRNA
does not require de novo protein synthesis, suggesting that in
trophoblast cells TNF-K transcription might be induced by
the well described posttranslational activation of NF-UB
and/or NF-UB-like molecules [33]. On the other hand, TNF-
K gene transcription was shown to be repressed by short-lived
DNA-binding proteins [34]. IL-1L might therefore facilitate
transcription by inactivating these repressors.
We found that TNF-K mRNA expression was highly up-
regulated in the presence of cycloheximide and IL-1L. Super-
induction of TNF-K mRNA has been explained by transla-
tional inhibition of a degrading RNase which mediates the
rapid turnover of the transcript via destabilizing elements in
the 3P region of the mRNA [35]. Indeed, in BeWo cells we
observed TNF-K mRNA induction after cycloheximide treat-
ment in the absence of IL-1L. Therefore, we assume that the
strong expression of TNF-K mRNA upon addition of both
substances was due to the combined e¡ect of cycloheximide-
induced stabilization of transcripts and IL-1-induced tran-
scriptional activation.
Interestingly, there is only a minor contribution of newly
synthesized TNF-K mRNA to the overall TNF-K expression,
since inducible TNF-K release was not abolished in cytotro-
phoblastic cells which had been translationally inhibited 2 h
before incubation with IL-1L. This result indicates that IL-1L
induces TNF-K secretion of constitutively synthesized TNF-K
protein without a requirement for new protein translation and
independently of stimulation of TNF-K mRNA expression.
This might by accomplished by posttranslational activation
of protease(s) which process the membrane-anchored pro-
TNF-K to the mature, secreted form by internal protein cleav-
age [36,37].
Finally, we demonstrate that growth arrested/di¡erentiated
BeWo cells express higher levels of TNF mRNA and secreted
protein than proliferating cells. However, TNF-K release was
found to be less inducible upon IL-1L treatment. This result
suggests that IL-1 type 1 receptors which were detected on
early gestation trophoblasts [23] might be downregulated dur-
ing trophoblast di¡erentiation but further studies are needed.
In summary, we demonstrate for the ¢rst time that IL-1 is a
potent inducer of TNF-K in cytotrophoblastic cells. Accord-
ingly, it is tempting to speculate that IL-1L, which is highly
expressed in ¢rst trimester trophoblasts but produced at low
levels in the third trimester [23], might also control TNF-K
expression in vivo and thereby in£uence trophoblast di¡eren-
tiation and/or turnover. On the other hand, in infected fetal
membranes, IL-1 released from placental macrophages, troph-
oblasts or other sources might induce secretion of large
amounts of trophoblast-derived TNF-K. This may enhance
in£ammatory reactions as well as cytotoxic e¡ects of TNF-K
on the trophoblast.
Acknowledgements: We thank W. Lajta, R. Kuzmits and U. Tretz-
mu
ë
ller for technical assistance, especially for preparation of puri¢ed
term trophoblast cells.
References
[1] Aggarwal, B.B. and Natarajan, K. (1996) Eur. Cytokine Netw. 7,
93^124.
[2] Wride, M.A. and Sanders, E.J. (1993) Dev. Dyn. 198, 225^239.
[3] Jacobsen, S.E.W., Ruscetti, F.W., Dubois, C.M. and Keller, J.R.
(1992) J. Exp. Med. 175, 1759^1772.
[4] Beutler, B., Milsark, I.W. and Cerami, A.C. (1985) Science 229,
869.
[5] Tartaglia, L.A. and Goeddel, D.V. (1992) Immunol. Today 13,
151^153.
[6] Pedersen, A.M., Fulton, S.K., Porter, L. and Francis, G.L.
(1995) J. Reprod. Immunol. 29, 69^80.
[7] Yamaguchi, M., Kurachi, H., Tadokoro, C., Sakata, M., Yoshi-
moto, Y., Masumoto, N., Tasaka, K. and Miyake, A. (1994)
Biochem. Biophys. Res. Commun. 202, 1599^1605.
[8] Casey, M.L., Cox, S.M., Beutler, B., Milewich, L. and Mc-
Donald, P.C. (1989) J. Clin. Invest. 83, 430^436.
[9] Jaattela, M., Kuusela, P. and Saksela, M.E. (1988) Lab. Invest.
58, 48^52.
[10] Crainie, M., Guilbert, L. and Wegmann, T.G. (1990) Biol. Re-
prod. 43, 999^1005.
[11] Yelavarthi, K.K., Chen, H.-L., Yang, Y., Cowley Jr., B.D., Fish-
back, J.L. and Hunt, S.J. (1991) J. Immunol. 146, 3840^3848.
[12] Chen, H.-L., Yang, Y., Hu, X.-L., Yelavarthi, K.K., Fishback,
J.L. and Hunt, J.S. (1991) Am. J. Pathol. 139, 327^335.
[13] Hampson, J., McLaughlin, P.J. and Johnson, P.M. (1993) Immu-
nology 79, 485^490.
[14] Yang, Y., Yelavarthi, K.K., Chen, H.-L., Pace, J.L., Terranova,
P.F. and Hunt, J.S. (1993) J. Immunol. 150, 5614^5624.
[15] Kliman, H.J., Nestler, J.E., Sermasi, E., Sanger, J.M. and Strauss
III, J.F. (1986) Endocrinology 118, 1567^1581.
[16] Kiss, H., Stefaner, I., Neuwirth, S., Reisenberger, K., Ellinger, A.
and Egarter, Ch. (1996) Geburtsh. Frauenheilkd. 56, Artikel 602,
1^8.
[17] McMaster, G.K. and Carmichael, G.G. (1977) Proc. Natl. Acad.
Sci. USA 74, 4835^4838.
[18] Yanushpolsky, E.H., Ozturk, M., Polgar, K., Berkowitz, R.S.
and Hill, J.A. (1993) J. Reprod. Immunol. 25, 235^247.
[19] Kauma, S., Matt, D., Strom, S., Eierman, D. and Turner, T.
(1990) Am. J. Obstet. Gynecol. 163, 1430^1437.
[20] Romero, R., Wu, Y.K., Broody, D., Oyarzun, E., Du¡, G.W.
and Durum, S.K. (1989) Obstet. Gynecol. 73, 31^34.
[21] Nestler, J.E. (1993) Endocrinology 132, 566^570.
[22] Yagel, S., Lala, P.K., Powell, W.A. and Casper, R.F. (1989)
J. Clin. Endocrinol. Metab. 68, 992^995.
[23] Librach, C.L., Feigenbaum, S.L., Bass, K.E., Cui, T.-Y., Vera-
stas, N., Sadovsky, Y., Quigley, J.P., French, D.L. and Fisher,
S.J. (1994) J. Biol. Chem. 269, 17125^17131.
[24] Lewis, M.P., Sullivan, M.F.H. and Elder, M.G. (1994) Placenta
15, 13^20.
[25] Yui, J., Garcia-Lloret, M., Wegmann, T.G. and Guilbert, L.J.
(1994) Placenta 15, 819^835.
[26] Yui, J., Hemmings, D., Garcia-Lloret, M. and Guilbert, L.J.
(1996) Biol. Reprod. 55, 400^409.
[27] Kelly, R.W., Carr, G.G., Elliott, C.L., Tulppala, M. and Critch-
ley H.O.D. (1995) Hum. Reprod. 10, 3289^3292.
FEBS 18335 24-10-97
M. Kno
ë
£er et al./FEBS Letters 405 (1997) 213^218 217
[28] Pauli, U. (1994) Crit. Rev. Eukaryotic Gene Expression 4, 323^
344.
[29] Shakhov, A.N., Collart, M.A., Vassalli, P., Nedospasov, S.A.
and Jongeneel, C.V. (1990) J. Exp. Med. 171, 35^47.
[30] Tsai, E.Y., Jain, J., Pesavento, P.A., Rao, A. and Goldfeld, A.E.
(1996) Mol. Cell. Biol. 16, 459^467.
[31] Bethea, J.R., Chung, I.Y., Sparacio, S.M., Gillespie, G.Y. and
Benveniste E.N. (1992) J. Neuroimmunol. 36, 179^191.
[32] LeBail, O., Schmidt-Ullrich, R. and Israel, A. (1993) EMBO J.
12, 5043^5049.
[33] Baeuerle, P.A. and Baltimore, D. (1988) Science 242, 540^546.
[34] Collart, M.A., Belin, D., Vassalli, J.D., de Kossodo, S. and Vas-
salli, P. (1986) J. Exp. Med. 173, 801^811.
[35] Han, J., Beutler, B. and Huez, G. (1991) J. Immunol. 146, 1843^
1848.
[36] Kim, K.U., Kwon, O.J. and Jue, D.M. (1993) Immunology 80,
134^139.
[37] Gearing, A.J.H., Beckett, M., Christodoulou, M., Churchill, R.,
Clements, J.M., Davidson, A.H., Drummond, A.H., Galloway,
W.A., Gilber, R., Gordon, J.L., Leber, T.M., Mangan, M., Mil-
ler, K., Nayee, P., Owen, K., Patel, S., Thomas, W., Wells, G.,
Wood, L.M. and Wooley, K. (1994) Nature 370, 555^557.
FEBS 18335 24-10-97
M. Kno
ë
£er et al./FEBS Letters 405 (1997) 213^218218
